Goldman Sachs Group Inc Spero Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$0.68 - $2.2 $168,478 - $545,078	-247,763 Reduced 81.72%	55,438 $111,000
Q3 2022 Nov 10, 2022	SELL	$0.68 - $2.2 $168,478 - $545,078	-247,763 Reduced 81.72%	55,438 $0
Q2 2022 May 14, 2024	BUY	$0.74 - $7.44 $224,368 - $2.26 Million	303,201 New	303,201 $225,000
Q2 2022 Aug 15, 2022	BUY	$0.74 - $7.44 $119,713 - $1.2 Million	161,775 Added 114.39%	303,201 $225,000
Q1 2022 May 16, 2022	BUY	$7.87 - $15.15 $22,154 - $42,647	2,815 Added 2.03%	141,426 $1.23 Million
Q4 2021 Feb 14, 2022	BUY	$13.09 - $18.77 $13,508 - $19,370	1,032 Added 0.75%	138,611 $2.22 Million
Q3 2021 Nov 10, 2021	BUY	$13.03 - $19.51 $1.79 Million - $2.68 Million	137,579 New	137,579 $2.53 Million

13.9M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $30.2M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.